Part of UT Health San Antonio

Part of UT Health San Antonio

You are here

Eugenio Cersosimo, M.D.

Contact

210-358-7200

cersosimo@uthscsa.edu

Departments & Divisions

Eugenio Cersosimo, M.D.

Associate Professor of Medicine/ Director of Clinical Research

Texas Diabetes Institute

Eugenio Cersosimo, MD, PhD is currently the medical director of clinical research at the Texas Diabetes Institute and an associate professor of medicine at the University of Texas Health Science Center in San Antonio, Texas. He is board certified in endocrinology, diabetes and metabolism and maintains an active practice in the adult outpatient clinic in San Antonio. Dr. Cersosimo graduated from medical school at the Universidade Federal Fluminense in Rio de Janeiro, Brazil in 1975 and obtained a doctorate degree in physiology at Vanderbilt University in Nashville, Tennessee in 1986. 

He completed his training in internal medicine and endocrinology, diabetes & metabolism in the Clinician Investigator Tract at the Mayo Clinic, Rochester, Minnesota in 1994. He started his academic career as an assistant professor of medicine at the State University of New York at Stony Brook, NY and in 2001 transferred to his current position at the University of Texas Health Science Center in San Antonio. 

Dr. Cersosimo has authored more than 60 original manuscripts and has received numerous research grants and awards from the National Institutes of Health, Juvenile Diabetes Foundation, American Diabetes Association, Kronkosky Foundation, Howard Hughes Institute, and from various pharmaceutical companies. Presently, he is directly involved in and supervises more than 20 different research projects in areas of his greatest interest: glucose regulation, the entero-pancreatic axis, and insulin therapy & insulin resistance with a focus on cardiovascular and renal complications.

  • Professional Background

    Education

    • 1994 - Clinical Fellowship - Endocrinology (awarded a R29 grant by National Institutes of Health) - Mayo Graduate School
    • 1991 - Residency - Medicine (NA) - Mayo Graduate School
    • 1987 - Postdoctoral Fellowship - Surgery and Endocrinology (NA) - Sloan Kettering Memorial
    • 1985 - PhD - Physiology (NA) - Vanderbilt University
    • 1975 - MD - Clinical Sciences (NA) - Universidade Federal Fluminense

    Appointments

    • 10/2015 - Associate Professor - Graduate School and UTHSCSA Graduate School - UTHSCSA, Diabetes, Obesity, Molecular Physiology, San Antonio
    • 3/2002 - Associate Professor / Clinical and Associate Professor of Medicine - University of Texas Health Science Center at San Antonio, Medicine, San Antonio

  • Instruction & Training

    • 10/2015 - Present, Clinical Research
    • 6/2002 - Present, Visiting Graduate Students, UTHSCSA
    • 6/2001 - Present, Medical Spupervision of Health Care Providers in the Outpatient Clinic, UTHSCSA
    • 6/2001 - Present, Rotation Student Supervision, UTHSCSA
    • 6/2001 - Present, Clinical Endocrinology, The University of Texas Health Science Center
    • 6/2001 - Present, Clinical Research
    • 6/2001 - Present, Clinical Endocrinology, The University of Texas Health Science Center

  • Research & Grants

    Grants

    Federal

    Funding Agency NIH Title Durability of Initial Triple Therapy in Diabetes Status Active Period 1/2009 - 8/2018 Role Co-Investigator Grant Detail Extended for additional 3 years with anticipated date of completion on December 2017

    Funding provided at the same level described for previous 5 years

    UTHSCSA, American Diabetes Association and Astra-Seneca Combined funding

    Funding Agency NIDDK Title Gradual Diabetes Treatment (GRADE) Status Active Period 6/2012 - 6/2018 Role Consultant Grant Detail NIH-sponsored prospective clinical trial looking for best combination agents in treatment of diabetes.

    Principal Investigator: Ralph DeFronzo,MD
    Co-Principal Investigator:Eugenio Cersosimo,MD PhD
    NIH/NIDDK (UO1 DK 098246-01)
    Total amount (5 years) = $1,794.660
    NCT = 01794143

     

    Private

    Funding Agency Janssen Pharmaceuticals Title Effect of Combined Incretin-Based Therapy Plus Canagliflozin On Glycemic Control and the Compensatory Rise in Hepatic Glucose Production in Type 2 Diabetic Patients Status Active Period 10/2015 - 9/2018 Role Principal Investigator Grant Detail Clinical evaluation of the combined effects of canagliflozin and liraglutide in the management of obese type 2 diabetes

    PRINCIPAL INVESTIGATOR: EUGENIO CERSOSIMO, MD, PhD
    Sponsored by Janssen Pharmaceuticals
    Total Amount = $1,852,632 (3 years)
    NCS = 02324842

    Funding Agency AstraZeneca Pharmaceutical Title AstraZeneca Dapa-Saxa Study Status Active Period 10/2015 - 9/2018 Role Principal Investigator Grant Detail Clinical evaluation of the combination therapy of saxagliptin and dapagliflozin in uncontrolled diabetes

    PRINCIPAL INVESTIGATOR: EUGENIO CERSOSIMO, MD, PhD Sponsored by Astra-Zeneca Pharmaceutical
    Total Amount = 2,137,434 (3 years)
    NCT = 02613897

    Funding Agency American Diabetes Association Title Preservation of beta-cell function in Pre-Diabetes Status Active Period 1/2014 - 6/2017 Role Co-Investigator Grant Detail Study examines potential agents capable of slowing progressive beta-cell deterioration in pre-diabetes individuals

    Principal Investigator - Ralph DeFronzo, MD
    Co-Investigator - Eugenio Cersosimo, MD PhD
    sponsored by the American Diabetes Association
    Total amount = $540,000 (3 years)
    NCS - not yet assigned

    Funding Agency VeroScience Title Effect of Cycloset on glycemic control in type 2 diabetic patients inadequately controlled on GLP-1 analogue Status Active Period 6/2014 - 6/2017 Role Co-Principal Investigator Grant Detail Randomized controlled trial to assess improvements in glucose control and in specific vascular surrogate markers using dynamic tests in uncontrolled type 2 diabetes ;patients receiving GLP-1 receptor analogue

  • Publications

      Abstract

      Cersosimo E, Xu X, Upala S, Triplitt C, Musi N. Acute insulin resistance stimulates and insulin sensitization attenuates vascular smooth muscle cell migration and proliferation: PubMed; 2014 Aug. (Physiol Rep; vol. 2, no. 8).

      Review Article

      Cersosimo E. Novel Agents for the Treatment of Type 2 Diabetes Diabetes Spectrum 2015 May;27(2):100-112. Eugenio Cersosimo, Carolina Solis-Herrera, Michael E. Trautmann, Jaret Malloy, Curtis L. Triplitt. Assessment of Pancreatic Beta-Cell Function: Review of Methods and Clinical Applications Current Diabetes Review, 2014 Dec;10(1). Cersosimo E. Renal glucose handling and the kidney as a target for anti-diabetic medication Current Trends in Endocrinology 2014 Mar;7:81-94.